1. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
- Author
-
Ishi Y, Yamaguchi S, Okamoto M, Sawaya R, Endo S, Motegi H, Terasaka S, Tanei ZI, Hatanaka KC, Tanaka S, and Fujimura M
- Subjects
- Adult, Humans, Isocitrate Dehydrogenase genetics, Isocitrate Dehydrogenase metabolism, Middle Aged, Mutation, Retrospective Studies, Brain Neoplasms diagnostic imaging, Brain Neoplasms enzymology, Brain Neoplasms genetics, Glioblastoma diagnostic imaging, Glioblastoma enzymology, Glioblastoma genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf metabolism
- Abstract
The aim of this study was to analyze the clinical and radiological characteristics of glioblastomas (GBMs) harboring a BRAF mutation. Sequencing analysis of BRAF, IDH1/2, and TERT promoters was performed on GBM samples of patients older than 15 years. The clinical, pathological, and radiological data of patients were retrospectively reviewed. Patients were classified into three groups according to their BRAF and IDH1/2 status: BRAF group, IDH group, and BRAF/IDH-wild-type (WT) group. Among 179 GBM cases, we identified nine cases with a BRAF mutation and nine with IDH mutation. The WT group had 161 cases. Age at onset in the BRAF group was significantly lower compared to the WT group and was similar to the IDH group. In cases with negative IDH1-R132H staining and age < 55 years, 15.2% were BRAF-mutant cases. Similar to the IDH group, overall survival of the BRAF group was significantly longer compared with the WT group. Among nine cases in the BRAF group, three cases had hemorrhagic onset and prior lesions were observed in two cases. In conclusion, age < 55 years, being IDH1-R132H negative, with hemorrhagic onset or the presence of prior lesions are factors that signal recommendation of BRAF analysis for adult GBM patients., (© 2022. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.)
- Published
- 2022
- Full Text
- View/download PDF